Paris, 13 July 2022. The strategy, leadership and development consulting firm Neovian Partners has accompanied the investment fund Calcium Capital in carrying out the Strategic Due Diligence – Buyer of Laukimax (ex-Groupe Eliote).

Founded in 1999 by Bruno Le Roy and Fernando Carvalho, GROUPE ELIOTE has become in a few years one of the major players in audiovisual media services for the production of flow programmes (entertainment, magazines, reports, reality shows, game shows, etc.).

In 2018, ELIOTE became the ELIOTE GROUP, whose organisation was then structured around 5 distinct areas of activity: rental of filming equipment, assistance with the production of audiovisual content and programmes, post-production, rental of editing rooms, recording of events and archiving. Henceforth named Laukimax, the Group has a turnover of 18 million euros and 80 employees spread over 5 sites between Boulogne and Paris.

Under the supervision of Patrick Richer (Founding Partner) and Arnaud François (Manager), Neovian Partners conducted a diagnostic of Laukimax’s market positioning, the synergies between its various entities and the Group’s growth levers in the years to come.

“ It was a pleasure to accompany Calcium Capital on this exciting project. In a market that has undergone many changes, notably as a result of Covid-19 and consolidation movements, Laukimax is a player with an original and differentiating positioning. “

Patrick Richer, Founding Partner, Neovian Partners

About Neovian Partners

Neovian Partners is a consulting firm specializing in the creation of tailored solutions in Strategy, Business Due Diligence, Strategic Screening and HR/Leadership, serving fast-growing investment funds, SMEs and MSCs. Based in Paris and Lyon with a team of about 30 consultants, Neovian Partners is also present internationally, with a network of partner firms with more than 500 employees in 21 countries. Neovian Partners is a generalist firm but with a particularly important project history in software, IT, Internet, Industry, Health and MedTechs, as well as in many niche sectors. More information on :